Insider · CIK 0001838139

Urist Marshall

Reports to the SEC for 1 company · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001838139

Forms 4 and 5

Insider transactions

46 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-05	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−4,126 sh	$57.10	−$236K	0
2026-09-28	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−4,126 sh	$57.88	−$239K	4,126
2026-08-07	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPG Gift	EVP, Research & Investments	GGift	−3,000 sh	—	—	244,412
2026-08-05	RPRXRoyalty Pharma plcA Award	EVP, Research & Investments	AAward	+8,252 sh	—	—	8,252
2026-07-01	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−9,099 sh	$55.88	−$508K	0
2026-06-24	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−9,098 sh	$55.18	−$502K	9,099
2026-05-20	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−13.7K sh	$52.75	−$722K	18,197
2026-05-14	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−13.7K sh	$53.06	−$726K	31,881
2026-05-06	RPRXRoyalty Pharma plcA Award	EVP, Research & Investments	AAward	+18.2K sh	—	—	45,565
2026-02-11	RPRXRoyalty Pharma plcA Award	EVP, Research & Investments	AAward	+20K sh	—	—	27,368
2026-01-30	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−20K sh	$41.09	−$822K	0
2026-01-23	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−20K sh	$40.26	−$805K	20,000
2026-01-16	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−20K sh	$39.52	−$790K	40,000
2026-01-09	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−20K sh	$40.78	−$816K	60,000
2026-01-02	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−20K sh	$38.48	−$770K	80,000
2025-12-26	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−20K sh	$39.32	−$786K	100,000
2025-12-19	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−20K sh	$38.38	−$768K	120,000
2025-12-16	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−20K sh	$38.32	−$766K	140,000
2025-12-05	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−23.3K sh	$39.15	−$914K	160,000
2025-12-05	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−18.2K sh	$39.15	−$714K	7,398
2025-12-01	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−23.3K sh	$39.93	−$932K	183,334
2025-12-01	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−18.2K sh	$39.90	−$728K	25,640
2025-11-07	RPRXRoyalty Pharma plcC Conversion	EVP, Research & Investments	CConversion	+160K sh	—	—	206,667
2025-11-07	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPC Conversion	EVP, Research & Investments	CConversion	−16K sh	—	—	247,412
2025-11-05	RPRXRoyalty Pharma plcA Award	EVP, Research & Investments	AAward	+4,626 sh	—	—	43,882
2025-08-08	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPG Gift	EVP, Research & Investments	GGift	−3,000 sh	—	—	263,412
2025-08-06	RPRXRoyalty Pharma plcA Award	EVP, Research & Investments	AAward	+2,772 sh	—	—	39,256
2025-05-16	RPRXRoyalty Pharma plc · Class E Ordinary SharesA Award	EVP, Research & Investments	AAward	+1.36M sh	—	—	1,356,528
2025-05-08	RPRXRoyalty Pharma plcA Award	EVP, Research & Investments	AAward	+36.5K sh	—	—	83,151
2024-08-12	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPG Gift	EVP, Research & Investments	GGift	−2,182 sh	—	—	126,412
2023-02-22	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−23.3K sh	$37.30	−$870K	46,667
2023-02-17	RPRXRoyalty Pharma plcC Conversion	EVP, Research & Investments	CConversion	+70K sh	—	—	70,000
2023-02-17	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPC Conversion	EVP, Research & Investments	CConversion	−7,000 sh	—	—	128,594
2022-07-26	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−19.7K sh	$43.20	−$852K	0
2022-07-25	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−3,600 sh	$43.05	−$155K	19,734
2022-06-24	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−23.3K sh	$43.19	−$1.01M	23,334
2022-05-16	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−23.3K sh	$39.85	−$930K	46,667
2022-05-11	RPRXRoyalty Pharma plcC Conversion	EVP, Research & Investments	CConversion	+70K sh	—	—	70,000
2022-05-11	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPC Conversion	EVP, Research & Investments	CConversion	−7,000 sh	—	—	205,594
2021-06-07	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−16.6K sh	$47.02	−$779K	0
2021-06-04	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−16.6K sh	$45.13	−$748K	16,568
2021-06-02	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−14.6K sh	$41.52	−$605K	33,134
2021-05-21	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−100 sh	$41.00	−$4,100	47,700
2021-05-20	RPRXRoyalty Pharma plcS Sale	EVP, Research & Investments	SSale	−1,900 sh	$41.08	−$78.1K	47,800
2021-05-07	RPRXRoyalty Pharma plcC Conversion	EVP, Research & Investments	CConversion	+49.7K sh	—	—	49,700
2021-05-07	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPC Conversion	EVP, Research & Investments	CConversion	−4,970 sh	—	—	142,594

Recent filings

Accepted (ET)
Oct 54
Urist Marshall0001838139-26-000028
SEC(opens sec.gov)
Sep 304
Urist Marshall0001838139-26-000026
SEC(opens sec.gov)
Aug 74
Urist Marshall0001838139-26-000024
SEC(opens sec.gov)
Jul 24
Urist Marshall0001838139-26-000022
SEC(opens sec.gov)
Jun 254
Urist Marshall0001838139-26-000020
SEC(opens sec.gov)
May 214
Urist Marshall0001838139-26-000018
SEC(opens sec.gov)
May 154
Urist Marshall0001838139-26-000016
SEC(opens sec.gov)
May 84
Urist Marshall0001838139-26-000014
SEC(opens sec.gov)
Feb 134
Urist Marshall0001838139-26-000012
SEC(opens sec.gov)
Feb 24
Urist Marshall0001838139-26-000010
SEC(opens sec.gov)
Jan 264
Urist Marshall0001838139-26-000008
SEC(opens sec.gov)
Jan 204
Urist Marshall0001838139-26-000006
SEC(opens sec.gov)
Jan 134
Urist Marshall0001838139-26-000004
SEC(opens sec.gov)
Jan 64
Urist Marshall0001838139-26-000002
SEC(opens sec.gov)
Dec 294
Urist Marshall0001838139-25-000014
SEC(opens sec.gov)
Dec 224
Urist Marshall0001838139-25-000012
SEC(opens sec.gov)
Dec 174
Urist Marshall0001838139-25-000010
SEC(opens sec.gov)
Dec 94
Urist Marshall0001838139-25-000008
SEC(opens sec.gov)

Companies

Royalty Pharma plcEVP, Research & InvestmentsRPRX

Address

C/O ROYALTY PHARMA PLC 110 EAST 59TH STREET

NEW YORK, NY, 10022